Efficacy
DISEASE PROGRESSION
At the data cutoff date, 219 (60%) patients in the serplulimab plus chemotherapy group and 129 (70%) in the placebo plus chemotherapy group had disease progression or had died. At the time of this final PFS analysis, serplulimab plus chemotherapy met the criteria for superiority in prolonging PFS over placebo plus chemotherapy. The median PFS assessed by the blinded independent radiological review committee (IRRC) was 5.8 months (95% confidence interval (CI), 5.7–6.9 months) in the serplulimab plus chemotherapy group and 5.3 months (95% CI, 4.3–5.6 months) in the placebo plus chemotherapy group (stratified hazard ratio (HR), 0.60; 95% CI, 0.48–0.75; 